Arx517 updates about the trial for me... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

Arx517 updates about the trial for metastatic castration resistant prostate cancer

Maxone73 profile image
1 Reply

”Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed

Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose”

biospace.com/article/releas...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Schwah profile image
Schwah

that’s encouraging yo say the least.

Schwah

You may also like...

Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer: some options

reatment-after-progression-in-metastatic-castration-resistant-prostate-cancer

Update On My Metastatic Prostate Cancer

2011 followed by Cyberknife and ADT for an extra-capsular recurrence in 2016-2017. In 2018, my PSA...

Castrate resistant prostate cancer

My Dad's Metastatic Prostate Cancer Update

MCRPC (metastatic castrate resistant prostate cancer). It moved from his prostate area (prostate...

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer